Advances in understanding the mechanisms of aging and successful efforts in extending lifespan in laboratory animals have made enhancing human healthspan more attainable. A key factor in aging and many diseases is the decline in nicotinamide adenine dinucleotide (NAD+) levels. Preclinical studies demonstrate promising results for NAD+ boosting in improving conditions of disease or aging. However, limited human studies have shown clinically significant improvements in physiological function or quality of life with NAD+ boosting supplements. This randomized, double-blind, placebo-controlled study (Clinicaltrails.gov identifier: NCT06505967) investigated the impact of Qualia NAD+® on blood NAD+ levels and healthy aging, as assessed by quality of life surveys. Methods: Sixty-three healthy adults aged 35 - 76 (62% female) consumed Qualia NAD+ (n = 28) or placebo (n = 35) for 28 consecutive days and had NAD+ assessed. NAD+ levels were measured at baseline and study end using a self-administered, non-invasive blood spot assay, and quality of life measures were reported weekly. Qualia NAD+ increased NAD+ levels by an average of 67% compared to 4% with placebo (p < 0.001). Within-group changes for Qualia NAD+ and between-groups comparisons were also significant (p < 0.001). Qualia NAD+ improved emotional well-being on days 14, 21, and 28, and vitality on days 21 and 28, versus placebo (all p < 0.05). Aging female symptoms improved in overall and somatic categories at day 28 (all p < 0.05). No significant improvements in aging symptoms were observed for males. In conclusion, NAD+ boosting with Qualia NAD+ enhanced quality of life in all participants and alleviated some aging symptoms in females.

S.A.B., W.S., G.K., and A.A. are employed by Qualia Life Sciences. S.A. and S.R. are consultants for Qualia Life Sciences. The funder provided Qualia NAD+ and was involved in the manuscript writing, editing, approval, and decision to publish.

NCT06505967

This research was funded by Qualia Life Sciences.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Advarra Institutional Review Board (independent institution) gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Other author email addresses: Blomquist SA (sblomqqualialife.com), Kelly G, (gregqualialife.com), Adães S (saraqualialife.com), Abhimanyu A. (Abhiqualialife.com), Ramer S (shawnqualialife.com)

The data presented in this study are available on reasonable request from the corresponding author due to ethical reasons that prevent public sharing.